Updated: Duplicate MAAs: Amgen Wins EU-wide Approval for Two Humira Biosimilars
By Zachary Brennan -
Published 24 March 2017
The European Commission (EC) on Thursday granted two marketing authorizations for Amgen’s biosimilars to AbbVie's blockbuster biologic Humira (adalimumab), known as Amgevita (adalimumab) and Solymbic (adalimumab).
Categories: News, Europe, EC, EMA, Biologics and biotechnology, Government affairs, Regulatory strategy, Submission and registration
Tags: Humira biosimilar, duplicate MAA, Amgen, Pfizer, Enbrel